Direct compression of azathioprine for low-dose tablet strengths such as 25 mg and 50 mg is constrained by the small mass fraction of active ingredient relative to the core weight, which routinely remains below 15% w/w when a 400 mg core is selected. The production-scale blend sequence normally begins with a geometric pre-mix: azathioprine is passed through a 0.5 mm stainless-steel screen together with an equal mass of lactose monohydrate or microcrystalline cellulose in a 100 L bin blender at 8–12 rpm for 10 min. This pre-mix is screened again before the remaining diluent, disintegrant, and binder are added. Content uniformity failure is the principal technical barrier; under USP <905> the acceptance value must not exceed 15.0 for the first 10 dosage units, and the full 30-unit tiered decision tree is applied when values fall between 15.0 and 25.0. Production-scale rotary tablet presses equipped with forced feeders and paddle speeds of 20–40 rpm are used, with compression force frequently maintained in the 8–18 kN range to produce tablet hardness of 40–80 N and friability below 1.0% under USP <1216>. Magnesium stearate is restricted to 1.0–1.5% w/w and added at the final blending stage for 3–5 min because extended lubrication reduces tensile strength through over-lubrication, a failure mode that is especially severe in low-dose, high-diluent formulations. Terminal dosage forms are immediate-release tablet cores intended for film coating; typical strengths are 25 mg, 50 mg, 75 mg, and 100 mg azathioprine per tablet. In-process verification includes stratified sampling at the beginning, middle, and end of compression to detect segregation drift, with individual tablet assay limits of 90.0–110.0% label claim. Because azathioprine is photolabile, coating pan windows and inspection stations use amber shielding, and tablets are packaged in aluminium-PVC blisters or amber glass.

What limits encapsulation speed when azathioprine is filled into hard gelatin capsules at 25 mg and 50 mg doses?

Because azathioprine API alone has poor flow and low bulk density, encapsulation at 25 mg and 50 mg doses relies on dosator-type capsule fillers rather than tamping-disc machines, since low fill weights require precise plug compaction. The API is pre-blended with microcrystalline cellulose or anhydrous lactose and colloidal silicon dioxide at 0.25–0.75% w/w to improve flow; magnesium stearate at 0.5–1.0% w/w represents the boundary between acceptable ejection and reduced dissolution caused by hydrophobic film formation. Powder bridging inside the hopper is the dominant field failure when bulk density falls below 0.45 g/cm³; conditioned bulk density is therefore raised to 0.55–0.65 g/cm³ by selecting densified diluents or by pre-compaction. Capsule size 2 or 1 is used for 25 mg and 50 mg strengths; the fill weight is typically 110–160 mg, giving drug loads between 15% and 22% w/w. In-process control requires weight checks at 5–10 min intervals using acceptance limits of ± 5% around the target fill weight, and content uniformity follows the same USP <905> tiered plan used for tablets. Dissolution testing under USP <711> uses a single-point acceptance criterion of Q = 75% at 45 min for immediate-release dosage forms. Terminal products are hard gelatin capsules retained in amber HDPE bottles with desiccant if the closure is not vapour-tight. Strongly alkaline excipients are avoided because azathioprine undergoes nucleophilic attack at the thioether bridge when the local micro-environment remains above neutral pH for extended wet-massing periods.

When a high-shear wet granulation route is selected for 100 mg azathioprine tablets, granule moisture and binder selection control both hardness and dissolution

High-shear wet granulation for 100 mg azathioprine tablets is selected when direct compression cannot maintain content uniformity across multiple API suppliers or when higher tablet hardness is required for film-coating. The process uses a high-shear granulator with an impeller speed of 150–300 rpm and a chopper speed of 1500–2500 rpm, with purified water or an aqueous binder solution sprayed at 2–5% w/w relative to dry powder mass. If polyvinylpyrrolidone is used as binder at 3–5% w/w, the granulation endpoint is reached when impeller amperage stabilizes and wet mass dampness is between 40–55%; endpoint control is more reproducible than timed addition because azathioprine bulk density varies between API suppliers. The wet granules are discharged through a 4–6 mm screen, dried in a fluid-bed dryer at inlet air temperature 50–60 °C until loss on drying is 1.5–2.5%, and milled through a 1.0–1.5 mm screen. Final blend includes croscarmellose sodium 2–4% w/w, microcrystalline cellulose, and magnesium stearate at 0.5–1.0% w/w; extended lubrication beyond 5 min decreases tensile strength and increases disintegration time to above 15 min in some scale-up studies. Tablet compression is performed to hardness of 70–120 N, friability ≤ 0.8%, and disintegration time ≤ 30 min in 37 °C water. Terminal products are film-coated tablets containing 100 mg azathioprine; subcoats may contain titanium dioxide or iron oxide light barriers because the API degrades upon extended UV exposure. Process validation includes granule particle-size distribution with D50 between 150 µm and 250 µm and moisture homogeneity. Published data for azathioprine-specific wet mass rheology is limited, so development batches should establish acceptable ranges rather than relying on platform defaults.For anhydrous granule intermediates, roller compaction avoids water contact and is suitable when azathioprine is intended for capsule-containing or moisture-sensitive packaging lines. The pre-blend is compacted at roll pressure 30–80 kN and roll speed 3–10 rpm; ribbon thickness of 2–4 mm is milled to granules with a D50 of 200–400 µm. Ribbon density is the critical control parameter because overdense ribbons above 1.20 g/cm³ can reduce compressibility and increase tensile failure in subsequent tablet compression. Milled granules are blended with extragranular croscarmellose sodium 2–3% w/w and magnesium stearate. This route is preferred when the API supplier's particle-size distribution is inconsistent, because roller compaction can homogenize the mixture; however, the granule fraction below 75 µm must not exceed 25–30% or segregation returns during high-speed tablet pressing. Terminal products include oral tablets and granules filled into hard capsules; content uniformity under USP <905> and dissolution under USP <711> remain batch-release requirements. On production lines, roller gap drift and ribbon splitting are the primary bottlenecks, and in-process ribbon density monitoring is more predictive of downstream tablet hardness than granule particle-size distribution alone.

Comparative operational targets for azathioprine oral solid intermediates

Intermediate	Typical drug load	Equipment type	Critical control target	Release/control standard
Direct compression blend	< 15% w/w for 25 mg/400 mg core	Rotary press with forced feeder	Hardness 40–80 N; friability < 1.0%	USP <905>, USP <1216>
Capsule powder blend	15–22% w/w in size 1/2	Dosator capsule filler	Fill weight ± 5%; bulk density 0.55–0.65 g/cm³	USP <905>, USP <711>
High-shear wet granulation	5–20% w/w after granulation	High-shear granulator/fluid-bed dryer	LOD 1.5–2.5%; D50 150–250 µm	USP <711>
Roller-compacted granules	10–30% w/w	Roller compactor with ribbon mill	Ribbon density 1.0–1.20 g/cm³; fines < 30% below 75 µm	USP <905>, USP <711>

Injectable lyophilizate: sodium salt conversion, glass delamination, and endotoxin control in azathioprine for parenteral use

Azathioprine for injection is supplied as a sterile lyophilized powder, normally the sodium salt equivalent to 100 mg azathioprine base per vial. The bulk API must be sterile or aseptically processed with a bioburden control strategy compliant with EU GMP Annex 1 and 21 CFR 210/211. Reconstitution with 10 mL Sterile Water for Injection produces a solution of approximately 10 mg/mL; the reconstituted pH is adjusted to 9.0–10.0 with sodium hydroxide, which maintains the sodium salt in solution but limits admixture compatibility with acidic infusion fluids because the drug converts rapidly to 6-mercaptopurine outside a narrow pH window. The filling line uses 0.22 µm sterilizing-grade filters, and the lyophilization cycle includes a primary drying shelf temperature of −25 °C to −15 °C and secondary drying up to 25 °C until residual moisture is ≤ 2.0% w/w. Vial selection is critical: Type I borosilicate glass is required because the alkaline reconstituted solution can extract aluminium and silicon from soda-lime glass, and visible delamination flakes have been reported when low-fill-volume vials are autoclaved under suboptimal conditions. Container-closure integrity is validated under USP <1207>; release testing follows USP <71> sterility, USP <85> bacterial endotoxins with the limit calculated from the maximum adult dose, and USP <787> subvisible particulate matter for particles ≥ 10 µm and ≥ 25 µm. The terminal dosage is a single-dose vial; after reconstitution, the solution is typically used within 24 hours at controlled room temperature. Because azathioprine is a cytotoxic hazardous drug, compounding and filling are conducted under containment consistent with USP <800>, with negative-pressure isolators and closed-system transfer devices.

Release and stability control matrix for azathioprine sodium lyophilized injection

Attribute	Method / Standard	Typical control target
Sterility	USP <71>	No growth after 14 days incubation
Bacterial endotoxins	USP <85>	Calculated from maximum adult dose; not a fixed value
Subvisible particulate matter	USP <787>	Particles ≥ 10 µm and ≥ 25 µm meet monograph limits
Residual moisture	Karl Fischer titration	≤ 2.0% w/w
Reconstituted pH	Potentiometric	9.0–10.0
Container-closure integrity	USP <1207>	No dye ingress after vacuum decay setpoint

Oral suspension granules are not a simple blend of tablet granules and sucrose

In unit-dose sachet production, granules for oral suspension and hospital compounding require a different particle-size and preservative strategy than tablet granulations. The granule intermediate is often produced by fluid-bed granulation with a binder solution containing hypromellose or povidone at 1–2% w/w; the dry granules are screened to a D50 of 180–300 µm and filled into aluminium sachets to exclude light and moisture. Reconstitution in purified water at a concentration of 50 mg/5 mL or 40 mg/mL for hospital compounding must consider sedimentation volume and redispersibility; xanthan gum or microcrystalline cellulose/carboxymethylcellulose sodium co-processed suspending agents are used at 0.5–1.5% w/w when the API is dispensed as a powder for suspension. Solubility limitations of azathioprine make a solution-based oral liquid difficult; a practically insoluble active requires suspension, and dose accuracy depends on vigorous shaking and rapid syringing after mixing. Preservatives are omitted when the product is packaged as a unit-dose sachet for immediate use; if a multi-dose bottle is compounded in the pharmacy, methylparaben or sodium benzoate is selected only after compatibility studies because azathioprine in alkaline media undergoes nucleophilic attack at the thioether bridge to release 6-mercaptopurine. Terminal finished forms include unit-dose sachets and bulk granules for hospital pharmacy dispensing; release tests include moisture content ≤ 2.0% w/w, content uniformity under USP <905>, and a modified USP <711> dissolution test with a validated medium. Experience on production lines shows that fluid-bed inlet air humidity above 60% RH causes granule agglomeration and should be pre-conditioned by dehumidification; published data for azathioprine oral suspension physical stability is limited, so beyond-use dates must be derived from chemical and microbial stability studies in the actual container.